FDA approves Onureg as continued treatment for adults in first remission with AML

This article was originally published here

AML is one of the most common acute leukemias in adults. The approval is based on results from the pivotal Phase 3 QUAZAR® AML-001 study in which treatment

The post FDA approves Onureg as continued treatment for adults in first remission with AML appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply